Bausch-lomb Incorporated

Pharmpur Gmbh

Joachim Dresp

Dirk-Henning Menz

Karin Kobuch

Hans Hoerauf

Martin Winter

Veit-Peter Gabel

Dirk Henning Menz

The invention includes a method for the passivation of the surface of an intraocular lens, wherein the surface includes Br&#xf6;nsted sites. The intraocular lens is dipped into a solution of a fluoroalkyl silane having the general formula: R&#x2014;(CH)&#x2014;Si&#x2014;(O&#x2014;R). The residue R is selected from the group of H, CH, CHand CHand the fluoroalkyl residue Ris selected from the series CF(CF), with m=3 to 11 and n=0 to 4. The Br&#xf6;nsted sites on the surface are thereby deactivated by formation of Si&#x2014;Q&#x2014;bonds.

Method for the passivation of an intraocular lens

The invention relates to a plastically deformable implant for inserting into bodily orifices of the human or animal body. Implants of this type are used, for example, in ophthalmology, in particular, as vitreous body or lens replacements and in dentistry, for example, for filling extraction cavities in jaw-bones. Known implants, however, are not suitable for long-term use. The invention aims to provide a deformable plastic implant which also has a long-term application. This is achieved by the fact that the implant consists of a gel which is not sealed, containing fluorocarbon and which is directly introduced into the natural, or artificially created bodily orifice.

Plastically deformable implant

A tear replacement solution that contains at least one water-soluble fluorosurfactant, water and a non-polar component, preferably in gel form, and a method for the external treatment for the eye of an mammal by applying the tear replacement solution to the eye, preferably by placing in the conjunctival sac.

Artificial tear replacement solution

The present invention concerns fluorocarbons for use in ophthalmology. Fluorocarbons disclosed in the prior art can only be left in the eye for a limited period of time because they cause damage to the retina or intraocular structure. The present invention provides an oxygen-fluorocarbon mixture having a dissolved oxygen content of less than 6% by volume, which can be used as an ophthalmological agent for longer periods of time than conventional fluorocarbons, with little or no damage to the retina or intraocular structures. The invention also provides a process for preparing the oxygen-fluorocarbon mixture. In one embodiment, up to 20% by volume of a second gas, such as carbon dioxide or nitric oxide, is combined with the oxygen-fluorocarbon mixtures.

Growing community of inventors

Munich, Germany

Joachim Dresp